Operator: Thank you. Our next question comes from David Amsellem with Piper Sandler.
David Amsellem: Thanks. So just a couple. First on vasopressin, can you just go through your thought process in more detail on the withdrawal? Is it just a function of the crowded nature of the market? Or are there other considerations? And then can you just talk to how you thought about the ROI on that given the withdrawal and was there a potential to come back at some point as you look in market conditions? So just a few on those. And then secondly on bendamustine, I guess it was sort of in early days with generic market formation, but can you talk about where you ultimately think things will settle out regarding both BENDEKA and BELRAPZO share, so something of a longer-term question there? Thank you.
Scott Tarriff: Yes. So, okay, let’s start with vaso, David. Thank you for the question. So, look, vasopressin was the only generic we’ve developed in the company’s history. We thought we had a unique capability of bringing the product to the market and getting through the courts, which we did. We sold quite a bit last year and a year that we launched it. But our business, the rest of our business is just so strong, right? The bendamustine market, the PEMFEXY market, we’re investing behind CAL02 and Enalare, there’s just no real room in the company for a generic product. So we exited these generic markets well as the price declines. There’s just no reason for us to be spending our time in our sales forces focus on a generic product.
In terms of coming back to the market, that’s really very interesting. Certainly, we have the capability of doing that if things change, we did have very good market share for the product. We don’t have big plans in the near future or anything that we see on the horizon. Considering that we just exited. But the ANDA is viable, so we’ll see how markets shake out, sometimes things change, that’s basically the vaso story. Now bendamustine, BENDEKA we’ve guided to keeping 75% of the gross margin in €˜23. So far 90 days into it, almost 90 days into it, we’re really encouraged, we’re ahead of our forecast and our plans, I think that speaks well to the strength of the benefits of the products. Let’s see how the months go, we’ll give more of an update when we close out Q1, what we report there.
But I mean, so far we’re thrilled about how the products are holding up and how the trends are working. And right now, again, we just feel great about bendamustine and quite frankly the entire line. So let’s see how things unfold, it’s going to be another really good strong year for us in €˜23.
David Amsellem: Thank you.
Scott Tarriff: Thank you.
Operator: Thank you. At this time, I show no further questions in queue. I’ll turn the call back to Scott Tarriff for any additional or closing remarks.
Scott Tarriff: Well, thank you everybody for joining the call. Look €˜22 is a record year for Eagle and we’re committed to carrying that momentum into €˜23 and beyond. Our team remains focused on delivering value to stakeholders and ensuring the patients have access to our therapeutics. We look forward to updating you as we continue to pursue growth organically and potentially through acquisitions. Thank everybody for joining today, I appreciate it and be healthy.
Operator: This concludes today’s call. Thank you for your participation. You may disconnect at any time.
